Eiger BioPharmaceuticals, Inc. – NASDAQ:EIGR
Founder-led company
Eiger BioPharmaceuticals stock price today
$1.725
-0.53
-23.67%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 3 hours
Eiger BioPharmaceuticals stock price monthly change
-61.10%
month
Eiger BioPharmaceuticals stock price quarterly change
+882.61%
quarter
Eiger BioPharmaceuticals stock price yearly change
+154.73%
year
Eiger BioPharmaceuticals key metrics
Market Cap | 2.55M |
Enterprise value | 85.61M |
P/E | -0.44 |
EV/Sales | 4.22 |
EV/EBITDA | -0.63 |
Price/Sales | 1.86 |
Price/Book | 0.68 |
PEG ratio | N/A |
EPS | -50.81 |
Revenue | 15.77M |
EBITDA | -69.24M |
Income | -74.96M |
Revenue Q/Q | 41.06% |
Revenue Y/Y | 16.97% |
Profit margin | -697.86% |
Oper. margin | -664.95% |
Gross margin | 89.64% |
EBIT margin | -664.95% |
EBITDA margin | -439.04% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEiger BioPharmaceuticals stock price history
Eiger BioPharmaceuticals stock forecast
Eiger BioPharmaceuticals financial statements
| Mar 2023 | 4.11M | -22.78M | -553.28% |
|---|---|---|---|
| Jun 2023 | 4.64M | -20.69M | -445.72% |
| Sep 2023 | 3.20M | -18.03M | -561.86% |
| Dec 2023 | 3.80M | -13.45M | -353.77% |
| 2027 | 36.15M | -3.54M | -9.8% |
|---|
Analysts Price target
Financials & Ratios estimates
| Mar 2023 | 99228000 | 63.98M | 64.49% |
|---|---|---|---|
| Jun 2023 | 72358000 | 57.06M | 78.86% |
| Sep 2023 | 55654000 | 57.25M | 102.88% |
| Dec 2023 | 38826000 | 53.28M | 137.24% |
| Mar 2023 | -24.00M | 13.38M | 41K |
|---|---|---|---|
| Jun 2023 | -22.03M | 29.84M | -22K |
| Sep 2023 | -14.55M | 19M | 15K |
| Dec 2023 | -13.95M | 11.99M | 7K |
Eiger BioPharmaceuticals alternative data
| Aug 2023 | 51 |
|---|---|
| Sep 2023 | 56 |
| Oct 2023 | 56 |
| Nov 2023 | 56 |
| Dec 2023 | 56 |
| Jan 2024 | 56 |
| Feb 2024 | 56 |
| Mar 2024 | 56 |
| Apr 2024 | 56 |
| May 2024 | 56 |
| Jun 2024 | 56 |
| Jul 2024 | 56 |
Eiger BioPharmaceuticals other data
89.90%
+19.42%
of EIGR is owned by hedge funds
91
+10
30.50M
+6.58M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2022 | 100000 | 27500 |
| Jan 2023 | 50000 | 0 |
| Mar 2023 | 0 | 4395 |
| Oct 2023 | 179173 | 0 |
| Nov 2023 | 123398 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | KAYNE RICHARD A 10 percent owner | Common Stock | 23,398 | $0.3 | $6,973 | ||
Purchase | KAYNE RICHARD A 10 percent owner | Common Stock | 100,000 | $0.28 | $28,000 | ||
Purchase | KAYNE RICHARD A 10 percent owner | Common Stock | 130,509 | $0.24 | $31,453 | ||
Purchase | KAYNE RICHARD A 10 percent owner | Common Stock | 12,345 | $0.26 | $3,234 | ||
Purchase | KAYNE RICHARD A 10 percent owner | Common Stock | 11,987 | $0.26 | $3,153 | ||
Purchase | KAWAS LEEN 10 percent owner | Common Stock | 12,345 | $0.26 | $3,234 | ||
Purchase | KAWAS LEEN 10 percent owner | Common Stock | 11,987 | $0.26 | $3,153 | ||
Sale | MAYER ELDON C. III | Common Stock | 1,875 | $1.07 | $2,008 | ||
Sale | MAYER ELDON C. III | Common Stock | 2,520 | $1.07 | $2,696 | ||
Purchase | DIETZ THOMAS JOHN director | Common Stock | 50,000 | $1.43 | $71,600 |
| Patent |
|---|
Grant Filling date: 18 Aug 2020 Issue date: 26 Apr 2022 |
Application Filling date: 10 Mar 2021 Issue date: 27 Jan 2022 |
Application Filling date: 10 Aug 2021 Issue date: 2 Dec 2021 |
Application Filling date: 27 Nov 2018 Issue date: 2 Dec 2021 |
Application Filling date: 15 Oct 2019 Issue date: 4 Nov 2021 |
Application Filling date: 3 May 2021 Issue date: 14 Oct 2021 |
Grant Filling date: 17 Apr 2020 Issue date: 14 Sep 2021 |
Application Filling date: 11 May 2021 Issue date: 2 Sep 2021 |
Application Filling date: 18 Feb 2021 Issue date: 29 Jul 2021 |
Application Filling date: 23 Aug 2019 Issue date: 24 Jun 2021 |
| Quarter | Transcript |
|---|---|
| Q3 2022 3 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 6 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 8 May 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2021 10 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. David A. Cory M.B.A., R.Ph., R.Ph, MBA (1964) Bus. Founder, Pres, Chief Executive Officer & Director | $1,000,000 |
| Mr. Eldon C. Mayer III, M.B.A. (1961) Executive Vice President & Chief Commercial Officer | $657,150 |
Mr. Sriram Ryali M.B.A. (1981) Chief Financial Officer | $567,120 |
| Dr. Evan Loh (1959) Chief Executive Officer of Paratek Pharmaceuticals & Director | $60,000 |
| Dr. Jeffrey S. Glenn (1963) Founder, Scientific Advisor & Independent Director | $57,500 |
Eiger BioPharmaceuticals: A Compelling High Beta Story
Biopharmaceutical Stocks Continue To Perform Well, With Many Attractive Values Remaining
Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst
Healthcare Sector Stock Performance Continues To Improve
Biopharmaceutical Stocks: The Bottoming Process Is Playing Out
Eiger Biopharmaceuticals: Value Inflection For Lead Asset In HDV Infection On The Horizon
-
What's the price of Eiger BioPharmaceuticals stock today?
One share of Eiger BioPharmaceuticals stock can currently be purchased for approximately $1.73.
-
When is Eiger BioPharmaceuticals's next earnings date?
Unfortunately, Eiger BioPharmaceuticals's (EIGR) next earnings date is currently unknown.
-
Does Eiger BioPharmaceuticals pay dividends?
No, Eiger BioPharmaceuticals does not pay dividends.
-
How much money does Eiger BioPharmaceuticals make?
Eiger BioPharmaceuticals has a market capitalization of 2.55M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 16.98% to 15.77M US dollars.
-
What is Eiger BioPharmaceuticals's stock symbol?
Eiger BioPharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "EIGR".
-
What is Eiger BioPharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Eiger BioPharmaceuticals?
Shares of Eiger BioPharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Eiger BioPharmaceuticals's key executives?
Eiger BioPharmaceuticals's management team includes the following people:
- Mr. David A. Cory M.B.A., R.Ph., R.Ph, MBA Bus. Founder, Pres, Chief Executive Officer & Director(age: 61, pay: $1,000,000)
- Mr. Eldon C. Mayer III, M.B.A. Executive Vice President & Chief Commercial Officer(age: 64, pay: $657,150)
- Mr. Sriram Ryali M.B.A. Chief Financial Officer(age: 44, pay: $567,120)
- Dr. Evan Loh Chief Executive Officer of Paratek Pharmaceuticals & Director(age: 66, pay: $60,000)
- Dr. Jeffrey S. Glenn Founder, Scientific Advisor & Independent Director(age: 62, pay: $57,500)
-
Is Eiger BioPharmaceuticals founder-led company?
Yes, Eiger BioPharmaceuticals is a company led by its founders Mr. David A. Cory M.B.A., R.Ph., R.Ph, MBA and Dr. Jeffrey S. Glenn.
-
How many employees does Eiger BioPharmaceuticals have?
As Jul 2024, Eiger BioPharmaceuticals employs 56 workers.
-
When Eiger BioPharmaceuticals went public?
Eiger BioPharmaceuticals, Inc. is publicly traded company for more then 11 years since IPO on 30 Jan 2014.
-
What is Eiger BioPharmaceuticals's official website?
The official website for Eiger BioPharmaceuticals is eigerbio.com.
-
Where are Eiger BioPharmaceuticals's headquarters?
Eiger BioPharmaceuticals is headquartered at 2155 Park Boulevard, Palo Alto, CA.
-
How can i contact Eiger BioPharmaceuticals?
Eiger BioPharmaceuticals's mailing address is 2155 Park Boulevard, Palo Alto, CA and company can be reached via phone at +65 02726138.
Eiger BioPharmaceuticals company profile:
Eiger BioPharmaceuticals, Inc.
eigerbio.comExchange:
NASDAQ
Full time employees:
56
Industry:
Biotechnology
Sector:
Healthcare
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
2155 Park Boulevard
Palo Alto, CA 94306
Palo Alto, CA 94306
CIK: 0001305253
ISIN: US28249U2042
CUSIP: 28249U105
